Total Payments
$7,786
2024 Payments
$1,507
Companies
58
Transactions
482
Medicare Patients
9,842
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$6,153 (79.0%)
Education$1,233 (15.8%)
Consulting$400.00 (5.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,153 | 464 | 79.0% |
| Education | $1,233 | 17 | 15.8% |
| Consulting Fee | $400.00 | 1 | 5.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $764.16 | 79 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $526.19 | 36 | $0 (2024) |
| PFIZER INC. | $507.52 | 43 | $0 (2024) |
| Daiichi Sankyo Inc. | $492.21 | 9 | $0 (2021) |
| Janssen Biotech, Inc. | $478.48 | 24 | $0 (2024) |
| Gilead Sciences, Inc. | $452.24 | 22 | $0 (2024) |
| Incyte Corporation | $435.75 | 14 | $0 (2024) |
| Merck Sharp & Dohme LLC | $362.60 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $349.87 | 22 | $0 (2024) |
| Eisai Inc. | $321.15 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,507 | 93 | E.R. Squibb & Sons, L.L.C. ($199.79) |
| 2023 | $1,137 | 62 | Gilead Sciences, Inc. ($221.68) |
| 2022 | $880.56 | 54 | Janssen Biotech, Inc. ($164.09) |
| 2021 | $548.50 | 31 | Janssen Biotech, Inc. ($124.44) |
| 2020 | $880.72 | 36 | Daiichi Sankyo Inc. ($435.60) |
| 2019 | $1,031 | 78 | E.R. Squibb & Sons, L.L.C. ($151.25) |
| 2018 | $1,153 | 92 | E.R. Squibb & Sons, L.L.C. ($173.13) |
| 2017 | $648.74 | 36 | Amgen Inc. ($122.34) |
All Payment Transactions
482 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $3.73 | General |
| Category: Hematology/Oncology | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $11.80 | General |
| Category: Hematology/Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $6.82 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $3.97 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.51 | General |
| Category: Oncology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $1.36 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.48 | General |
| 11/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.00 | General |
| 10/10/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $17.16 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.59 | General |
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.77 | General |
| Category: Oncology | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $0.30 | General |
| Category: Oncology | ||||||
| 09/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $17.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 2,462 | 32,331 | $1.6M | $425,733 |
| 2022 | 26 | 2,126 | 25,652 | $955,550 | $356,913 |
| 2021 | 29 | 2,319 | 51,181 | $1.1M | $444,403 |
| 2020 | 35 | 2,935 | 129,792 | $1.3M | $462,735 |
Total Patients
9,842
Total Services
238,956
Medicare Billing
$1.7M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 246 | 776 | $122,609 | $50,519 | 41.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 23 | 2,800 | $189,600 | $46,420 | 24.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,460 | $157,140 | $45,610 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 326 | 613 | $93,886 | $43,805 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 115 | 368 | $84,658 | $38,709 | 45.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 14 | 4,480 | $120,400 | $28,277 | 23.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 167 | 198 | $83,457 | $28,174 | 33.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 45 | 190 | $108,624 | $21,523 | 19.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 26 | 3,560 | $176,960 | $20,206 | 11.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 87 | 87 | $38,340 | $15,449 | 40.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 18 | 8,580 | $67,340 | $11,762 | 17.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 68 | 469 | $57,505 | $11,539 | 20.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 370 | 1,368 | $24,839 | $10,978 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 358 | 1,296 | $41,330 | $9,855 | 23.8% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 23 | 93 | $23,013 | $7,318 | 31.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 48 | 111 | $29,018 | $5,984 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 40 | $12,424 | $5,842 | 47.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 99 | 112 | $10,300 | $4,832 | 46.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 301 | $24,495 | $3,578 | 14.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 53 | $16,270 | $3,007 | 18.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 27 | 122 | $14,130 | $3,001 | 21.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 43 | $8,490 | $2,633 | 31.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 29 | 163 | $15,115 | $2,157 | 14.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 16 | 112 | $8,056 | $1,956 | 24.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 21 | 1,020 | $105,190 | $809.83 | 0.8% |
About Dr. Ethan Wasserman, MD
Dr. Ethan Wasserman, MD is a Hematology & Oncology healthcare provider based in Hamilton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1811104292.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ethan Wasserman, MD has received a total of $7,786 in payments from pharmaceutical and medical device companies, with $1,507 received in 2024. These payments were reported across 482 transactions from 58 companies. The most common payment nature is "Food and Beverage" ($6,153).
As a Medicare-enrolled provider, Wasserman has provided services to 9,842 Medicare beneficiaries, totaling 238,956 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Hamilton, NJ
- Active Since 05/16/2007
- Last Updated 02/09/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1811104292
Products in Payments
- Enhertu (Drug) $423.49
- OPDIVO (Biological) $396.36
- ERLEADA (Drug) $349.65
- KEYTRUDA (Biological) $303.90
- Trodelvy (Drug) $300.05
- Lenvima (Drug) $281.38
- Imbruvica (Drug) $158.20
- IBRANCE (Drug) $154.56
- XTANDI (Drug) $149.35
- PADCEV (Biological) $133.44
- TASIGNA (Drug) $129.38
- JEVTANA (Drug) $128.16
- Stivarga (Drug) $123.17
- ADCETRIS (Biological) $114.85
- OPDUALAG (Drug) $97.87
- LIBTAYO (Biological) $96.30
- CALQUENCE (Drug) $85.81
- VERZENIO (Drug) $85.26
- JAKAFI (Drug) $81.87
- KISQALI (Drug) $77.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.